for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zoetis Inc

ZTS.N

Latest Trade

219.32USD

Change

-3.85(-1.73%)

Volume

391,923

Today's Range

218.52

 - 

225.50

52 Week Range

141.41

 - 

228.88

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
223.17
Open
222.27
Volume
391,923
3M AVG Volume
30.16
Today's High
225.50
Today's Low
218.52
52 Week High
228.88
52 Week Low
141.41
Shares Out (MIL)
473.13
Market Cap (MIL)
103,766.00
Forward P/E
47.18
Dividend (Yield %)
0.46

Next Event

Q4 2021 Zoetis Inc Earnings Release

Latest Developments

More

Zoetis Announces Third Quarter 2021 Results

Catalent Announces Chief Financial Officer Succession

Zoetis Reports Q1 EPS $1.17

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zoetis Inc

Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.

Industry

Biotechnology & Drugs

Contact Info

10 Sylvan Way

PARSIPPANY, NJ

07054-3825

United States

+1.973.8227000

https://www.zoetis.com/

Executive Leadership

Michael B. Mccallister

Non-Executive Independent Chairman of the Board

Kristin C. Peck

Chief Executive Officer, Director

Wetteny N. Joseph

Chief Financial Officer, Executive Vice President, Head of Business Development

Roxanne Lagano

Chief Human Resource Officer, Executive Vice President and Global Operations

Wafaa Mamilli

Executive Vice President, Chief Information and Digital Officer

Key Stats

1.76 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

5.8K

2019

6.3K

2020

6.7K

2021(E)

7.7K
EPS (USD)

2018

3.130

2019

3.640

2020

3.850

2021(E)

4.648
Price To Earnings (TTM)
52.82
Price To Sales (TTM)
13.62
Price To Book (MRQ)
22.19
Price To Cash Flow (TTM)
42.79
Total Debt To Equity (MRQ)
140.88
LT Debt To Equity (MRQ)
140.88
Return on Investment (TTM)
16.81
Return on Equity (TTM)
14.43

Latest News

Latest News

Zoetis donates animal COVID-19 vaccine candidate to about 70 U.S. zoos

Animal health company Zoetis Inc said on Friday it had donated over 11,000 doses of its experimental COVID-19 vaccine to nearly 70 zoos across the United States.

Pet adoption, spending get a boost from pandemic: Zoetis CEO

The COVID-19 pandemic has given a boost to pet adoptions and prompted people to spend more on pet care, said Kristin Peck, chief executive of Zoetis Inc, the world's largest animal health company, in an interview at the Reuters Next conference.

BRIEF-Trianni And Zoetis Announce Agreement To Develop A Transgenic Antibody Discovery Platform For Use In Animal Health

* TRIANNI AND ZOETIS ANNOUNCE AGREEMENT TO DEVELOP A TRANSGENIC ANTIBODY DISCOVERY PLATFORM FOR USE IN ANIMAL HEALTH

BRIEF-VIB Vermoegen Q1 Adjusted EBT Up At EUR 14.6 Mln

* CONTINUES ITS SUCCESSFUL GROWTH TRAJECTORY IN THE FIRST QUARTER OF 2020

BRIEF-Zoetis Says Pricing Of $1.25 Billion Of Senior Notes

* AGREED TO SELL $1.25 BILLION OF SENIOR NOTES, CONSISTING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.000% SENIOR NOTES DUE 2030

BRIEF-Zoetis Files Prospectus Supplement Related To A Potential Two-Part Senior Notes Offering - SEC Filing

* ZOETIS INC FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART SENIOR NOTES OFFERING - SEC FILING

BRIEF-Zoetis Reports Q1 Adjusted Earnings Per Share $0.95

* Q1 REVENUE $1.5 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.5 BILLION

Animal health leader Zoetis steps into pet insurance

Zoetis Inc <ZTS.N>, the world's largest animal health company, unveiled a new insurance unit in a bid to take advantage of rising pet ownership as Americans adopt furry companions to help relieve the loneliness of coronavirus lockdowns.

BRIEF-Zoetis Recommends Stockholders Reject Mini-Tender Offer By TRC Capital Investment Corp

* ZOETIS RECOMMENDS STOCKHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL INVESTMENT CORPORATION Source text for Eikon: Further company coverage:

BRIEF-Zoetis Says CEO Juan Ramón Alaix's FY 2019 Total Compensation Was $21.1 Mln Vs $11.7 Mln In 2018

* ZOETIS INC SAYS CEO JUAN RAMÓN ALAIX'S FY 2019 TOTAL COMPENSATION WAS $21.1 MILLION VERSUS $11.7 MILLION IN 2018 - SEC FILING

BRIEF-Zoetis Receives FDA Approval For Simparica Trio

* ZOETIS RECEIVES FDA APPROVAL FOR SIMPARICA TRIO™, A NEW COMBINATION PARASITE PREVENTATIVE FOR DOGS

BRIEF-Zoetis Reports Q4 EPS Of $0.80

* Q4 REVENUE $1.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.64 BILLION

BRIEF-Zoetis Inc Acquires Ethos Diagnostic Science

* ZOETIS ACQUIRES ETHOS DIAGNOSTIC SCIENCE, A VETERINARY REFERENCE LAB BUSINESS, TO FURTHER EXPAND ITS COMPREHENSIVE DIAGNOSTICS CAPABILITIES

Factbox: Animal health sector aims to emulate Zoetis biotech leap

A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis <ZTS.N> has roused rivals to action in a hunt for biotechnology medicines to treat pets.

Biotech is going to the dogs - and big profits await

For Jessica Lescault there is no question that her 6-year old English bulldog "Moose" deserves cutting-edge biotechnology cancer treatment as much as any human patient.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up